The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, nonrandomized, Phase 1b, dose-escalation study designed
to determine maximum tolerated dose (MTD) of CKD-516 in combination with durvalumab and
evaluate the safety and tolerability profile, efficacy of CKD-516 and durvalumab treatment.